David Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. He recently served as president and chief executive officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO.
Before joining Ajinomoto, David served as Head of Lonza’s Viral Therapeutics Business Unit, which resulted from Lonza’s acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded in June 2009 and where he served as president and CEO until its sale to Lonza AG. Under David’s leadership, the business experienced rapid expansion, with revenues increasing 500% over three years.
Preceding Vivante, Enloe spent 14 years with a biotech company, Introgen Therapeutics, joining as its first employee in 1995 and serving as senior vice president and COO before being named president and CEO. David was an integral part in taking the company through a successful IPO in 2020 and several other significant financial transactions. In addition, he oversaw multiple extensive corporate and academic collaborations and the filing of license applications with both the FDA and European regulatory authorities of Introgen’s lead product.
David received a Bachelor of Business Administration, Accounting from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.
What is J. David Enloe, Jr.'s net worth?
The estimated net worth of J. David Enloe, Jr. is at least $0.00 as of August 28th, 2023. Mr. Enloe, Jr. owns 1,098,940 shares of Recro Pharma stock worth more than $0 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Enloe, Jr. may own. Learn More about J. David Enloe, Jr.'s net worth.
How do I contact J. David Enloe, Jr.?
Has J. David Enloe, Jr. been buying or selling shares of Recro Pharma?
J. David Enloe, Jr. has not been actively trading shares of Recro Pharma in the last ninety days. Most recently, on Tuesday, March 15th, J David Enloe, Jr. bought 512 shares of Recro Pharma stock. The stock was acquired at an average cost of $1.96 per share, with a total value of $1,003.52. Learn More on J. David Enloe, Jr.'s trading history.
Who are Recro Pharma's active insiders?
